NTHI Announces NEO212 Phase 1 Dose Escalation Results, RP2D 610 mg, Phase 2 Initiation, FDA Type B Meeting Requested
NeOnc Technologies Holdings, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.54
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS